In Vitro Efficacy
Study-purpose endpoints may include cell viability, candidate responses, mechanism-related readouts and biomarkers.
PRECLINICAL EFFICACY · 3D BIOIMAGING
From cell-based and in vivo efficacy
to tissue-level 3D quantification
LEA BIO combines in vitro efficacy, in vivo pharmacology and histopathology with tissue-clearing 3D bioimaging and AI quantification when advanced spatial evidence is needed. We connect early candidate screening with tissue-level evidence in one expandable research workflow.
01 SERVICE OVERVIEW
FROM EFFICACY TO 3D EVIDENCE
Integrated nonclinical support,
connected stage by stage
We begin with cell-level responses, extend into animal models and tissue analysis, and add 3D spatial evidence when the research question calls for it.
Services can be selected individually or connected by development stage. Following a preliminary review of the model, sample, target and desired outputs, we recommend a suitable study design.
This is a nonclinical research support service; results should not be directly interpreted as clinical efficacy in humans.02 CORE SERVICES
INTEGRATED NONCLINICAL SUPPORT
Start with the evaluation you need
and extend to 3D evidence
Initial focus areas include oncology, kidney function and toxicity, and natural or functional materials. Detailed scope is determined after reviewing the objective and model.
In Vivo Pharmacology
Animal models, dosing conditions, comparison groups and efficacy endpoints are planned around the research objective.
Histopathology & Biomarkers
Tissue-level changes and target proteins are stained, imaged and quantitatively compared across groups.
3D Bioimaging & AI
Tissue clearing, 3D imaging and AI-assisted quantification reveal spatial changes in cells, vessels and targets.
FOCUSOncologyKidney Function & ToxicityNatural & Functional Materials
SERVICE PACKAGES
Three options aligned to study stage
In Vitro Package
Cell-based candidate screening and confirmation of core efficacy endpoints
Integrated Efficacy Package
In Vitro + In Vivo + histopathology and biomarker analysis
LEA BIO 3D Advanced
Integrated efficacy study + tissue clearing + 3D AI quantification + research report
03 3D ADVANCED APPLICATIONS
ADVANCED SPATIAL EVIDENCE
3D Advanced applications
added to core efficacy studies
Representative models where tissue clearing and 3D quantification can extend a core efficacy study. Existing samples and new models can be custom-designed after preliminary review.
015xFAD · Aβ plaque
Brain Pathology & Dementia
We compare the three-dimensional distribution and volume of target signals, including amyloid-beta plaques, across whole-brain tissue.
02MCAO
Cerebral Ischemia & Vascular Change
We visualize vascular architecture and neural target changes in ischemic brain tissue and design quantitative endpoints.
03BBB permeability
Blood–Brain Barrier
We evaluate whether candidate materials or labeled signals cross the blood–brain barrier and map their spatial distribution in tissue.
04UUO
Kidney Toxicity
We observe whole kidney tissue and glomeruli in 3D and compare changes in volume and distribution in kidney injury models.
05Optic nerve crush
Optic Nerve Injury
We examine changes in target cells and neural structures across whole tissue in optic nerve injury models.
06Retinal vasculature
Diabetic Retinopathy
We compare spatial changes in retinal vessels and pathological targets using 3D images and quantitative data.
07Cell distribution
Cell Therapy Distribution
We analyze the location, distribution range and persistence of administered cells within target organs in three dimensions.
08Particle accumulation
Microplastic Accumulation
We visualize and quantify the organ-specific accumulation sites and signal levels of labeled microparticles in 3D.
04 STUDY WORKFLOW
DESIGN · IN VITRO · IN VIVO · PATHOLOGY · 3D
From study design to integrated reporting
- 01
Study Design
We review the objective, candidate, model and comparison groups to define the evaluation strategy.
- 02
In Vitro Evaluation
Cell-based responses and core biomarkers are assessed to refine the next stage.
- 03
In Vivo Evaluation
Efficacy and pharmacology endpoints are evaluated under the agreed model and dosing conditions.
- 04
Pathology & 3D Analysis
We analyze pathology and biomarkers, adding tissue clearing and 3D quantification when appropriate.
- 05
Integrated Reporting
Study data are organized into comparable images, quantitative results and a research report.
05 DELIVERABLES
RESEARCH OUTPUT
Results designed to support
your next research decision
Detailed formats and analytical items are finalized during study-plan consultation.
Efficacy & Pharmacology Data
Group-comparison results for agreed endpoints from cell-based and in vivo studies
Pathology & Imaging Results
Representative tissue images, biomarker analysis and optional 3D source and quantitative data
Integrated Research Report
A report describing study conditions, analytical methods, key results and interpretation limits
PROJECT INQUIRY
Tell us about your research objective and samples.
We review the model, tissue type, target, sample size and desired outputs to recommend an appropriate evaluation strategy.